| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glaucoma | 78 | 2025 | 100 | 20.210 |
Why?
|
| Glaucoma, Open-Angle | 71 | 2025 | 83 | 17.670 |
Why?
|
| Intraocular Pressure | 97 | 2025 | 132 | 10.970 |
Why?
|
| Visual Fields | 57 | 2025 | 76 | 7.930 |
Why?
|
| Vision Disorders | 34 | 2024 | 61 | 7.220 |
Why?
|
| Ophthalmology | 22 | 2024 | 34 | 6.870 |
Why?
|
| Medicare | 19 | 2026 | 332 | 6.740 |
Why?
|
| Visual Acuity | 47 | 2024 | 111 | 5.920 |
Why?
|
| Trabeculectomy | 28 | 2025 | 32 | 5.600 |
Why?
|
| Cataract Extraction | 11 | 2026 | 23 | 5.190 |
Why?
|
| Vision Screening | 11 | 2022 | 21 | 4.880 |
Why?
|
| Aged | 145 | 2026 | 8214 | 4.410 |
Why?
|
| Strabismus | 12 | 2025 | 18 | 4.400 |
Why?
|
| Medicare Part B | 14 | 2025 | 16 | 4.300 |
Why?
|
| Refractive Errors | 10 | 2022 | 28 | 4.100 |
Why?
|
| Eye Diseases | 11 | 2025 | 29 | 4.040 |
Why?
|
| Retrospective Studies | 72 | 2025 | 2544 | 3.930 |
Why?
|
| Cataract | 13 | 2026 | 47 | 3.910 |
Why?
|
| Aged, 80 and over | 83 | 2026 | 2853 | 3.790 |
Why?
|
| Humans | 257 | 2026 | 43102 | 3.660 |
Why?
|
| United States | 66 | 2026 | 5205 | 3.620 |
Why?
|
| Macular Degeneration | 18 | 2025 | 31 | 3.600 |
Why?
|
| Optic Nerve Diseases | 28 | 2025 | 30 | 3.540 |
Why?
|
| Cross-Sectional Studies | 66 | 2026 | 3156 | 3.360 |
Why?
|
| Glaucoma Drainage Implants | 17 | 2025 | 17 | 3.340 |
Why?
|
| Female | 183 | 2026 | 24698 | 3.290 |
Why?
|
| Exfoliation Syndrome | 12 | 2022 | 13 | 2.970 |
Why?
|
| Male | 157 | 2026 | 23409 | 2.930 |
Why?
|
| Optic Disk | 24 | 2025 | 25 | 2.830 |
Why?
|
| Amblyopia | 6 | 2021 | 13 | 2.760 |
Why?
|
| Prevalence | 36 | 2025 | 1612 | 2.730 |
Why?
|
| Vision, Low | 9 | 2023 | 13 | 2.640 |
Why?
|
| Endophthalmitis | 5 | 2022 | 6 | 2.580 |
Why?
|
| Risk Factors | 56 | 2025 | 3994 | 2.350 |
Why?
|
| Follow-Up Studies | 42 | 2025 | 1067 | 2.260 |
Why?
|
| California | 14 | 2026 | 548 | 2.210 |
Why?
|
| Retinal Ganglion Cells | 20 | 2025 | 49 | 2.210 |
Why?
|
| Tomography, Optical Coherence | 23 | 2025 | 38 | 2.120 |
Why?
|
| Middle Aged | 91 | 2025 | 12222 | 1.880 |
Why?
|
| Accidental Falls | 8 | 2017 | 33 | 1.800 |
Why?
|
| Glaucoma, Neovascular | 2 | 2025 | 3 | 1.780 |
Why?
|
| Fractures, Bone | 8 | 2017 | 63 | 1.760 |
Why?
|
| Diabetic Retinopathy | 7 | 2025 | 78 | 1.730 |
Why?
|
| Quality of Life | 11 | 2026 | 616 | 1.730 |
Why?
|
| Nutrition Surveys | 7 | 2023 | 263 | 1.720 |
Why?
|
| Refraction, Ocular | 4 | 2024 | 48 | 1.700 |
Why?
|
| Myopia | 3 | 2023 | 27 | 1.700 |
Why?
|
| Musculoskeletal System | 3 | 2021 | 12 | 1.670 |
Why?
|
| Academies and Institutes | 5 | 2024 | 39 | 1.640 |
Why?
|
| Eyeglasses | 5 | 2016 | 22 | 1.630 |
Why?
|
| Prospective Studies | 39 | 2025 | 1600 | 1.610 |
Why?
|
| Nerve Fibers | 15 | 2025 | 37 | 1.560 |
Why?
|
| Risk Assessment | 9 | 2025 | 863 | 1.530 |
Why?
|
| Registries | 5 | 2024 | 437 | 1.520 |
Why?
|
| Social Class | 2 | 2025 | 291 | 1.520 |
Why?
|
| Glaucoma, Angle-Closure | 6 | 2023 | 8 | 1.510 |
Why?
|
| Delivery of Health Care | 5 | 2020 | 310 | 1.500 |
Why?
|
| Incidence | 21 | 2025 | 1078 | 1.500 |
Why?
|
| Vision, Binocular | 4 | 2017 | 8 | 1.480 |
Why?
|
| Leadership | 3 | 2024 | 86 | 1.480 |
Why?
|
| Hip Fractures | 3 | 2024 | 29 | 1.480 |
Why?
|
| Allergens | 3 | 2018 | 65 | 1.420 |
Why?
|
| Antihypertensive Agents | 16 | 2022 | 287 | 1.410 |
Why?
|
| Mass Screening | 3 | 2024 | 541 | 1.400 |
Why?
|
| Health Services Accessibility | 6 | 2026 | 706 | 1.340 |
Why?
|
| Cardiovascular Diseases | 4 | 2025 | 749 | 1.300 |
Why?
|
| Child, Preschool | 18 | 2026 | 1546 | 1.280 |
Why?
|
| Postoperative Complications | 11 | 2020 | 263 | 1.240 |
Why?
|
| Adult | 53 | 2025 | 13872 | 1.210 |
Why?
|
| Program Evaluation | 2 | 2026 | 359 | 1.200 |
Why?
|
| Scotoma | 4 | 2012 | 4 | 1.170 |
Why?
|
| Macula Lutea | 5 | 2021 | 7 | 1.160 |
Why?
|
| Population Surveillance | 5 | 2020 | 246 | 1.150 |
Why?
|
| Child | 25 | 2025 | 3443 | 1.130 |
Why?
|
| Tonometry, Ocular | 23 | 2020 | 27 | 1.120 |
Why?
|
| Oculomotor Muscles | 9 | 2021 | 14 | 1.100 |
Why?
|
| Societies, Medical | 4 | 2024 | 74 | 1.100 |
Why?
|
| Disease Progression | 21 | 2025 | 667 | 1.080 |
Why?
|
| Practice Guidelines as Topic | 6 | 2024 | 223 | 1.060 |
Why?
|
| Women's Health | 6 | 2018 | 160 | 1.050 |
Why?
|
| Astigmatism | 2 | 2024 | 16 | 1.030 |
Why?
|
| Retinal Vein Occlusion | 2 | 2025 | 2 | 1.020 |
Why?
|
| Healthcare Disparities | 4 | 2025 | 590 | 1.020 |
Why?
|
| Los Angeles | 8 | 2026 | 394 | 0.980 |
Why?
|
| Odds Ratio | 11 | 2025 | 587 | 0.970 |
Why?
|
| Mobile Health Units | 1 | 2026 | 8 | 0.970 |
Why?
|
| Low Tension Glaucoma | 1 | 2025 | 2 | 0.960 |
Why?
|
| Blood Pressure | 6 | 2025 | 666 | 0.930 |
Why?
|
| Sleep Disorders, Circadian Rhythm | 1 | 2025 | 3 | 0.930 |
Why?
|
| Keratoconus | 1 | 2025 | 18 | 0.910 |
Why?
|
| Vision, Ocular | 3 | 2022 | 43 | 0.910 |
Why?
|
| Immunoglobulin E | 2 | 2015 | 61 | 0.900 |
Why?
|
| Esotropia | 2 | 2022 | 3 | 0.890 |
Why?
|
| Exotropia | 2 | 2022 | 3 | 0.890 |
Why?
|
| Sickness Impact Profile | 5 | 2020 | 25 | 0.880 |
Why?
|
| Air Pollution, Indoor | 2 | 2015 | 53 | 0.880 |
Why?
|
| Greece | 16 | 2025 | 21 | 0.850 |
Why?
|
| Faculty, Medical | 1 | 2024 | 74 | 0.830 |
Why?
|
| Air Pollutants | 2 | 2015 | 130 | 0.820 |
Why?
|
| Treatment Outcome | 17 | 2025 | 1604 | 0.810 |
Why?
|
| Dementia | 2 | 2024 | 160 | 0.810 |
Why?
|
| Ocular Hypertension | 16 | 2017 | 17 | 0.800 |
Why?
|
| Eye Movements | 5 | 2025 | 16 | 0.790 |
Why?
|
| Niacin | 1 | 2023 | 23 | 0.780 |
Why?
|
| Rural Population | 1 | 2026 | 373 | 0.770 |
Why?
|
| Retinal Detachment | 2 | 2022 | 3 | 0.770 |
Why?
|
| Mydriatics | 3 | 2022 | 6 | 0.750 |
Why?
|
| Young Adult | 18 | 2025 | 5080 | 0.740 |
Why?
|
| Urban Population | 4 | 2019 | 374 | 0.730 |
Why?
|
| Eye Injuries | 1 | 2021 | 6 | 0.720 |
Why?
|
| Health Fairs | 1 | 2021 | 4 | 0.710 |
Why?
|
| Craniocerebral Trauma | 1 | 2021 | 22 | 0.710 |
Why?
|
| Public Health | 1 | 2026 | 424 | 0.700 |
Why?
|
| Laser Therapy | 8 | 2015 | 25 | 0.700 |
Why?
|
| Dexamethasone | 2 | 2022 | 55 | 0.690 |
Why?
|
| Optic Nerve | 7 | 2025 | 30 | 0.690 |
Why?
|
| Ciliary Body | 2 | 2019 | 14 | 0.690 |
Why?
|
| Insurance Claim Review | 2 | 2014 | 37 | 0.670 |
Why?
|
| Lens, Crystalline | 2 | 2018 | 39 | 0.670 |
Why?
|
| Osteoporosis, Postmenopausal | 8 | 2012 | 21 | 0.650 |
Why?
|
| Ophthalmologic Surgical Procedures | 4 | 2017 | 5 | 0.640 |
Why?
|
| Forecasting | 2 | 2019 | 136 | 0.620 |
Why?
|
| Macular Edema | 2 | 2025 | 5 | 0.620 |
Why?
|
| Personal Autonomy | 1 | 2019 | 22 | 0.620 |
Why?
|
| Keratoplasty, Penetrating | 2 | 2017 | 2 | 0.610 |
Why?
|
| Laser Coagulation | 1 | 2019 | 3 | 0.600 |
Why?
|
| Adolescent | 16 | 2025 | 6081 | 0.590 |
Why?
|
| Eye Infections, Bacterial | 2 | 2015 | 3 | 0.590 |
Why?
|
| Ocular Hypotension | 2 | 2017 | 2 | 0.590 |
Why?
|
| Schools | 2 | 2018 | 283 | 0.580 |
Why?
|
| Retinal Vessels | 3 | 2019 | 29 | 0.580 |
Why?
|
| Health Services Research | 5 | 2014 | 161 | 0.570 |
Why?
|
| Filtering Surgery | 1 | 2018 | 2 | 0.570 |
Why?
|
| Corneal Transplantation | 1 | 2018 | 2 | 0.570 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2018 | 42 | 0.570 |
Why?
|
| Hypersensitivity, Immediate | 1 | 2018 | 9 | 0.570 |
Why?
|
| Alkylating Agents | 6 | 2025 | 14 | 0.560 |
Why?
|
| Gonioscopy | 5 | 2022 | 5 | 0.560 |
Why?
|
| Anti-Bacterial Agents | 3 | 2022 | 432 | 0.550 |
Why?
|
| Carbonated Beverages | 1 | 2017 | 21 | 0.550 |
Why?
|
| Coffee | 1 | 2017 | 20 | 0.540 |
Why?
|
| Tea | 1 | 2017 | 46 | 0.540 |
Why?
|
| Mitomycin | 5 | 2025 | 13 | 0.540 |
Why?
|
| Prostaglandins, Synthetic | 4 | 2020 | 4 | 0.530 |
Why?
|
| Lenses, Intraocular | 2 | 2015 | 25 | 0.530 |
Why?
|
| Dietary Fats | 1 | 2018 | 117 | 0.520 |
Why?
|
| School Nursing | 2 | 2014 | 12 | 0.520 |
Why?
|
| Aqueous Humor | 2 | 2019 | 18 | 0.520 |
Why?
|
| Reoperation | 6 | 2025 | 34 | 0.520 |
Why?
|
| Fatty Acids | 1 | 2018 | 134 | 0.510 |
Why?
|
| Sex Distribution | 6 | 2024 | 224 | 0.510 |
Why?
|
| Age Distribution | 6 | 2024 | 249 | 0.510 |
Why?
|
| Glucocorticoids | 1 | 2017 | 91 | 0.500 |
Why?
|
| Patient Education as Topic | 1 | 2018 | 235 | 0.500 |
Why?
|
| National Eye Institute (U.S.) | 2 | 2013 | 3 | 0.490 |
Why?
|
| Databases, Factual | 6 | 2025 | 341 | 0.490 |
Why?
|
| Pre-Eclampsia | 1 | 2017 | 67 | 0.490 |
Why?
|
| Cohort Studies | 11 | 2023 | 1759 | 0.480 |
Why?
|
| Hypertension | 4 | 2019 | 835 | 0.470 |
Why?
|
| Health Resources | 2 | 2014 | 37 | 0.470 |
Why?
|
| Surgical Wound Infection | 1 | 2015 | 22 | 0.470 |
Why?
|
| Anterior Chamber | 3 | 2015 | 12 | 0.450 |
Why?
|
| Lens Implantation, Intraocular | 2 | 2014 | 16 | 0.450 |
Why?
|
| Randomized Controlled Trials as Topic | 8 | 2019 | 375 | 0.450 |
Why?
|
| Prosthesis Implantation | 7 | 2020 | 16 | 0.430 |
Why?
|
| Health Care Costs | 4 | 2016 | 91 | 0.430 |
Why?
|
| Case-Control Studies | 11 | 2025 | 1285 | 0.430 |
Why?
|
| Laser-Doppler Flowmetry | 2 | 2019 | 19 | 0.430 |
Why?
|
| Exercise | 1 | 2020 | 692 | 0.420 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2018 | 497 | 0.410 |
Why?
|
| Parents | 2 | 2014 | 370 | 0.400 |
Why?
|
| Evidence-Based Medicine | 2 | 2004 | 107 | 0.400 |
Why?
|
| Guideline Adherence | 2 | 2011 | 98 | 0.400 |
Why?
|
| Eye Proteins | 2 | 2025 | 63 | 0.390 |
Why?
|
| Phacoemulsification | 3 | 2020 | 19 | 0.390 |
Why?
|
| Fee-for-Service Plans | 4 | 2017 | 21 | 0.380 |
Why?
|
| Pupil | 1 | 2012 | 9 | 0.380 |
Why?
|
| National Institutes of Health (U.S.) | 2 | 2023 | 120 | 0.380 |
Why?
|
| Glycoproteins | 2 | 2025 | 125 | 0.380 |
Why?
|
| Iron, Dietary | 1 | 2012 | 13 | 0.380 |
Why?
|
| Cytoskeletal Proteins | 2 | 2025 | 116 | 0.380 |
Why?
|
| Health Education | 2 | 2013 | 363 | 0.380 |
Why?
|
| Health Services Needs and Demand | 4 | 2016 | 154 | 0.370 |
Why?
|
| Retinal Neoplasms | 2 | 2023 | 11 | 0.370 |
Why?
|
| School Health Services | 1 | 2013 | 90 | 0.370 |
Why?
|
| Retinoblastoma | 2 | 2023 | 16 | 0.370 |
Why?
|
| Mandatory Programs | 1 | 2011 | 5 | 0.360 |
Why?
|
| Calcium, Dietary | 1 | 2012 | 65 | 0.360 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2025 | 62 | 0.360 |
Why?
|
| Statistics as Topic | 2 | 2009 | 123 | 0.350 |
Why?
|
| Ophthalmoscopy | 9 | 2014 | 12 | 0.350 |
Why?
|
| Time Factors | 7 | 2016 | 1857 | 0.340 |
Why?
|
| Proportional Hazards Models | 7 | 2017 | 518 | 0.340 |
Why?
|
| Vegetables | 2 | 2012 | 147 | 0.340 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2025 | 183 | 0.340 |
Why?
|
| Activities of Daily Living | 4 | 2024 | 139 | 0.340 |
Why?
|
| Quality Assurance, Health Care | 1 | 2011 | 55 | 0.340 |
Why?
|
| Health Status | 3 | 2013 | 442 | 0.340 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2025 | 587 | 0.330 |
Why?
|
| Logistic Models | 7 | 2018 | 1009 | 0.330 |
Why?
|
| Shoulder Fractures | 1 | 2010 | 2 | 0.330 |
Why?
|
| Fruit | 2 | 2012 | 178 | 0.330 |
Why?
|
| Orthotic Devices | 1 | 2010 | 5 | 0.330 |
Why?
|
| Dietary Supplements | 1 | 2012 | 213 | 0.330 |
Why?
|
| Prognosis | 5 | 2019 | 861 | 0.330 |
Why?
|
| Academic Medical Centers | 2 | 2024 | 76 | 0.330 |
Why?
|
| Blindness | 4 | 2022 | 19 | 0.320 |
Why?
|
| Residence Characteristics | 1 | 2013 | 363 | 0.320 |
Why?
|
| Estrogen Replacement Therapy | 3 | 2008 | 42 | 0.320 |
Why?
|
| Postural Balance | 1 | 2010 | 37 | 0.320 |
Why?
|
| Physician-Patient Relations | 3 | 2016 | 148 | 0.310 |
Why?
|
| Retinal Diseases | 2 | 2022 | 20 | 0.310 |
Why?
|
| Severity of Illness Index | 5 | 2024 | 719 | 0.310 |
Why?
|
| Orbit | 3 | 2025 | 11 | 0.310 |
Why?
|
| Diabetes Mellitus | 3 | 2012 | 539 | 0.300 |
Why?
|
| Cause of Death | 3 | 2018 | 186 | 0.300 |
Why?
|
| Physical Examination | 2 | 2021 | 45 | 0.290 |
Why?
|
| Contrast Sensitivity | 3 | 2017 | 34 | 0.290 |
Why?
|
| Longitudinal Studies | 10 | 2025 | 1063 | 0.290 |
Why?
|
| Uveitis | 2 | 2021 | 5 | 0.290 |
Why?
|
| Comorbidity | 6 | 2018 | 737 | 0.280 |
Why?
|
| Retinoscopy | 3 | 2018 | 11 | 0.280 |
Why?
|
| Corneal Diseases | 3 | 2018 | 11 | 0.280 |
Why?
|
| Aging | 3 | 2025 | 783 | 0.280 |
Why?
|
| Health Surveys | 4 | 2018 | 405 | 0.270 |
Why?
|
| Drug Utilization | 1 | 2007 | 34 | 0.270 |
Why?
|
| DNA | 2 | 2025 | 592 | 0.270 |
Why?
|
| Diet | 3 | 2019 | 826 | 0.270 |
Why?
|
| Patient Care | 2 | 2004 | 31 | 0.260 |
Why?
|
| Geography | 2 | 2020 | 110 | 0.260 |
Why?
|
| Electronic Health Records | 3 | 2023 | 108 | 0.250 |
Why?
|
| Neoplasms | 1 | 2018 | 1377 | 0.250 |
Why?
|
| Adrenergic beta-Antagonists | 3 | 2016 | 54 | 0.250 |
Why?
|
| Anterior Eye Segment | 3 | 2015 | 9 | 0.250 |
Why?
|
| Linear Models | 6 | 2013 | 317 | 0.240 |
Why?
|
| International Classification of Diseases | 1 | 2006 | 27 | 0.240 |
Why?
|
| Bayes Theorem | 5 | 2025 | 126 | 0.240 |
Why?
|
| Amino Acid Oxidoreductases | 2 | 2017 | 37 | 0.240 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2021 | 863 | 0.230 |
Why?
|
| Caregivers | 2 | 2019 | 197 | 0.230 |
Why?
|
| Subarachnoid Space | 1 | 2025 | 3 | 0.230 |
Why?
|
| Optic Neuropathy, Ischemic | 1 | 2025 | 2 | 0.230 |
Why?
|
| Sensitivity and Specificity | 5 | 2021 | 611 | 0.230 |
Why?
|
| Cerebrospinal Fluid | 1 | 2025 | 20 | 0.220 |
Why?
|
| Elasticity | 1 | 2025 | 53 | 0.220 |
Why?
|
| Cost-Benefit Analysis | 1 | 2026 | 179 | 0.220 |
Why?
|
| Publications | 1 | 2004 | 10 | 0.220 |
Why?
|
| Smoking | 2 | 2023 | 1024 | 0.220 |
Why?
|
| Occupational Diseases | 1 | 2025 | 53 | 0.220 |
Why?
|
| Cornea | 1 | 2025 | 70 | 0.220 |
Why?
|
| Blepharoplasty | 1 | 2004 | 1 | 0.220 |
Why?
|
| Endpoint Determination | 3 | 2015 | 8 | 0.220 |
Why?
|
| Frail Elderly | 1 | 2004 | 18 | 0.210 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2025 | 296 | 0.210 |
Why?
|
| Income | 1 | 2025 | 160 | 0.210 |
Why?
|
| Occupational Exposure | 1 | 2025 | 91 | 0.210 |
Why?
|
| Keratoconjunctivitis | 1 | 2023 | 1 | 0.210 |
Why?
|
| Conjunctivitis, Allergic | 1 | 2023 | 2 | 0.210 |
Why?
|
| Timolol | 1 | 2003 | 3 | 0.210 |
Why?
|
| Alcohol Drinking | 1 | 2009 | 609 | 0.210 |
Why?
|
| Socioeconomic Factors | 2 | 2025 | 1234 | 0.210 |
Why?
|
| Pregnancy Complications | 1 | 2005 | 140 | 0.210 |
Why?
|
| Cognition Disorders | 3 | 2015 | 243 | 0.200 |
Why?
|
| Optic Nerve Glioma | 1 | 2023 | 1 | 0.200 |
Why?
|
| Neurofibromatosis 1 | 1 | 2023 | 5 | 0.200 |
Why?
|
| Thiophenes | 1 | 2003 | 32 | 0.200 |
Why?
|
| Educational Status | 1 | 2025 | 339 | 0.200 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2024 | 89 | 0.200 |
Why?
|
| Geriatrics | 1 | 2004 | 67 | 0.200 |
Why?
|
| Sulfonamides | 1 | 2003 | 91 | 0.190 |
Why?
|
| Professional Practice | 1 | 2002 | 6 | 0.190 |
Why?
|
| Insurance, Physician Services | 1 | 2002 | 1 | 0.190 |
Why?
|
| Economics, Medical | 1 | 2002 | 3 | 0.190 |
Why?
|
| Pregnancy | 4 | 2023 | 1772 | 0.190 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2002 | 18 | 0.190 |
Why?
|
| Specialization | 1 | 2002 | 26 | 0.190 |
Why?
|
| Research | 1 | 2004 | 181 | 0.190 |
Why?
|
| Steroids | 1 | 2022 | 45 | 0.180 |
Why?
|
| Research Design | 2 | 2023 | 385 | 0.180 |
Why?
|
| Fractures, Spontaneous | 3 | 2010 | 6 | 0.180 |
Why?
|
| Sodium Chloride, Dietary | 1 | 2022 | 39 | 0.180 |
Why?
|
| Infant, Newborn | 5 | 2023 | 972 | 0.180 |
Why?
|
| Lipids | 1 | 2003 | 256 | 0.180 |
Why?
|
| Infant | 7 | 2023 | 1175 | 0.180 |
Why?
|
| Technology | 1 | 2021 | 29 | 0.180 |
Why?
|
| Microcephaly | 1 | 2021 | 21 | 0.170 |
Why?
|
| Mutation | 2 | 2025 | 1177 | 0.170 |
Why?
|
| Schizophrenia | 1 | 2022 | 93 | 0.170 |
Why?
|
| Germ-Line Mutation | 1 | 2021 | 75 | 0.170 |
Why?
|
| Sensory Deprivation | 1 | 2021 | 7 | 0.170 |
Why?
|
| Atropine | 1 | 2021 | 12 | 0.170 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2021 | 82 | 0.170 |
Why?
|
| Uveal Neoplasms | 1 | 2021 | 11 | 0.170 |
Why?
|
| Uveitis, Anterior | 1 | 2020 | 1 | 0.170 |
Why?
|
| Hospitals, Veterans | 2 | 2018 | 15 | 0.170 |
Why?
|
| Minority Groups | 2 | 2023 | 690 | 0.170 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2023 | 192 | 0.170 |
Why?
|
| Employment | 1 | 2021 | 86 | 0.170 |
Why?
|
| Autoimmune Diseases | 1 | 2021 | 65 | 0.170 |
Why?
|
| Choroid | 1 | 2020 | 11 | 0.160 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 94 | 0.160 |
Why?
|
| Axons | 2 | 2012 | 117 | 0.160 |
Why?
|
| Graft Survival | 2 | 2018 | 47 | 0.160 |
Why?
|
| Anisometropia | 1 | 2019 | 3 | 0.160 |
Why?
|
| Hyperopia | 1 | 2019 | 7 | 0.160 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2021 | 117 | 0.160 |
Why?
|
| Prostaglandins | 2 | 2016 | 23 | 0.160 |
Why?
|
| Melanoma | 1 | 2021 | 110 | 0.150 |
Why?
|
| Acute Disease | 2 | 2017 | 155 | 0.150 |
Why?
|
| Algorithms | 5 | 2017 | 509 | 0.150 |
Why?
|
| Ophthalmic Solutions | 3 | 2016 | 18 | 0.150 |
Why?
|
| Lasers, Solid-State | 1 | 2019 | 12 | 0.150 |
Why?
|
| Endoscopy | 1 | 2019 | 17 | 0.150 |
Why?
|
| Costs and Cost Analysis | 1 | 2019 | 60 | 0.150 |
Why?
|
| Immunotherapy | 1 | 2020 | 144 | 0.150 |
Why?
|
| Reproducibility of Results | 7 | 2018 | 1081 | 0.150 |
Why?
|
| Adipose Tissue | 1 | 2020 | 182 | 0.140 |
Why?
|
| Focus Groups | 3 | 2016 | 423 | 0.140 |
Why?
|
| Motor Vehicles | 1 | 2018 | 14 | 0.140 |
Why?
|
| Calcium Channels | 2 | 2017 | 73 | 0.140 |
Why?
|
| Ophthalmoplegia | 1 | 2017 | 3 | 0.140 |
Why?
|
| Drug Administration Schedule | 1 | 2018 | 153 | 0.140 |
Why?
|
| Australia | 1 | 2018 | 103 | 0.140 |
Why?
|
| Age Factors | 2 | 2019 | 1154 | 0.130 |
Why?
|
| Genome-Wide Association Study | 2 | 2017 | 423 | 0.130 |
Why?
|
| Beverages | 1 | 2017 | 66 | 0.130 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2017 | 53 | 0.130 |
Why?
|
| Point Mutation | 1 | 2017 | 98 | 0.130 |
Why?
|
| Tomography | 3 | 2013 | 9 | 0.130 |
Why?
|
| Health Priorities | 1 | 2016 | 25 | 0.130 |
Why?
|
| Survival Rate | 1 | 2018 | 355 | 0.130 |
Why?
|
| Foreign-Body Migration | 2 | 2009 | 3 | 0.130 |
Why?
|
| Eyelids | 1 | 2016 | 4 | 0.130 |
Why?
|
| Mutation, Missense | 1 | 2017 | 91 | 0.130 |
Why?
|
| Regional Blood Flow | 3 | 2019 | 53 | 0.130 |
Why?
|
| Pilot Projects | 4 | 2015 | 760 | 0.130 |
Why?
|
| Polymorphism, Genetic | 2 | 2015 | 201 | 0.120 |
Why?
|
| Multivariate Analysis | 3 | 2019 | 638 | 0.120 |
Why?
|
| Parasympathomimetics | 1 | 2015 | 1 | 0.120 |
Why?
|
| Carbonic Anhydrase Inhibitors | 1 | 2015 | 7 | 0.120 |
Why?
|
| Ultrasonography | 1 | 2016 | 135 | 0.120 |
Why?
|
| Polytetrafluoroethylene | 1 | 2015 | 6 | 0.120 |
Why?
|
| Iris | 1 | 2015 | 11 | 0.120 |
Why?
|
| Amnion | 1 | 2015 | 16 | 0.120 |
Why?
|
| Glycosaminoglycans | 1 | 2015 | 24 | 0.120 |
Why?
|
| Gelatin | 1 | 2015 | 17 | 0.120 |
Why?
|
| Health Status Disparities | 1 | 2022 | 719 | 0.120 |
Why?
|
| Sensation Disorders | 1 | 2015 | 6 | 0.120 |
Why?
|
| Gait Disorders, Neurologic | 1 | 2015 | 11 | 0.120 |
Why?
|
| Combined Modality Therapy | 3 | 2025 | 173 | 0.120 |
Why?
|
| Mitochondrial Diseases | 1 | 2015 | 20 | 0.120 |
Why?
|
| Blood Pressure Determination | 2 | 2013 | 54 | 0.120 |
Why?
|
| Clinical Trials as Topic | 1 | 2017 | 259 | 0.120 |
Why?
|
| Surgically-Created Structures | 1 | 2015 | 1 | 0.110 |
Why?
|
| Eye Infections, Fungal | 1 | 2015 | 2 | 0.110 |
Why?
|
| Acupuncture Therapy | 1 | 2015 | 12 | 0.110 |
Why?
|
| United States Food and Drug Administration | 1 | 2015 | 29 | 0.110 |
Why?
|
| Family | 1 | 2016 | 195 | 0.110 |
Why?
|
| Collagen | 1 | 2015 | 181 | 0.110 |
Why?
|
| Population Groups | 1 | 2015 | 59 | 0.110 |
Why?
|
| Hearing Loss | 2 | 2004 | 16 | 0.110 |
Why?
|
| Prosthesis Design | 1 | 2014 | 47 | 0.110 |
Why?
|
| Biocompatible Materials | 1 | 2015 | 108 | 0.110 |
Why?
|
| Models, Biological | 5 | 2014 | 712 | 0.110 |
Why?
|
| Achievement | 1 | 2014 | 24 | 0.110 |
Why?
|
| Medical Staff, Hospital | 1 | 2014 | 15 | 0.110 |
Why?
|
| Substance-Related Disorders | 1 | 2022 | 830 | 0.100 |
Why?
|
| DNA, Mitochondrial | 1 | 2015 | 191 | 0.100 |
Why?
|
| Glare | 1 | 2013 | 4 | 0.100 |
Why?
|
| Risk | 2 | 2012 | 287 | 0.100 |
Why?
|
| Dark Adaptation | 1 | 2013 | 17 | 0.100 |
Why?
|
| Eye | 3 | 2024 | 77 | 0.100 |
Why?
|
| Calcium Channel Blockers | 1 | 2013 | 55 | 0.100 |
Why?
|
| Diuretics | 1 | 2013 | 51 | 0.100 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2013 | 78 | 0.100 |
Why?
|
| Data Collection | 1 | 2014 | 210 | 0.100 |
Why?
|
| Drug Therapy, Combination | 1 | 2013 | 234 | 0.100 |
Why?
|
| Predictive Value of Tests | 5 | 2018 | 440 | 0.100 |
Why?
|
| Quality Indicators, Health Care | 1 | 2013 | 49 | 0.100 |
Why?
|
| Geographic Atrophy | 1 | 2012 | 1 | 0.100 |
Why?
|
| Perception | 1 | 2014 | 215 | 0.090 |
Why?
|
| Light Coagulation | 1 | 2012 | 1 | 0.090 |
Why?
|
| Genetic Variation | 2 | 2012 | 430 | 0.090 |
Why?
|
| Observer Variation | 2 | 2014 | 59 | 0.090 |
Why?
|
| Internship and Residency | 1 | 2014 | 146 | 0.090 |
Why?
|
| Administration, Topical | 2 | 2020 | 39 | 0.090 |
Why?
|
| Osteoporosis | 1 | 2012 | 45 | 0.090 |
Why?
|
| Receptors, Chemokine | 1 | 2012 | 72 | 0.090 |
Why?
|
| Communication | 1 | 2014 | 210 | 0.090 |
Why?
|
| Professional Misconduct | 1 | 2011 | 2 | 0.090 |
Why?
|
| Conflict of Interest | 1 | 2011 | 11 | 0.090 |
Why?
|
| Mood Disorders | 2 | 2022 | 54 | 0.090 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2017 | 734 | 0.090 |
Why?
|
| Eye Abnormalities | 1 | 2011 | 7 | 0.090 |
Why?
|
| Aniridia | 1 | 2011 | 2 | 0.090 |
Why?
|
| Technology Assessment, Biomedical | 1 | 2011 | 12 | 0.090 |
Why?
|
| Molteno Implants | 2 | 2017 | 2 | 0.090 |
Why?
|
| Persuasive Communication | 1 | 2011 | 9 | 0.090 |
Why?
|
| Public Health Practice | 1 | 2011 | 39 | 0.080 |
Why?
|
| False Positive Reactions | 4 | 2013 | 28 | 0.080 |
Why?
|
| Lasers | 5 | 2012 | 57 | 0.080 |
Why?
|
| Retinal Artery | 1 | 2010 | 1 | 0.080 |
Why?
|
| Graft Rejection | 1 | 2010 | 43 | 0.080 |
Why?
|
| Photography | 5 | 2013 | 50 | 0.080 |
Why?
|
| DNA Mutational Analysis | 2 | 2025 | 95 | 0.080 |
Why?
|
| Homeodomain Proteins | 1 | 2011 | 150 | 0.080 |
Why?
|
| Hydrophthalmos | 1 | 2009 | 1 | 0.080 |
Why?
|
| Alleles | 3 | 2017 | 352 | 0.080 |
Why?
|
| Double-Blind Method | 2 | 2015 | 317 | 0.080 |
Why?
|
| Life Expectancy | 1 | 2009 | 72 | 0.070 |
Why?
|
| Progestins | 1 | 2008 | 11 | 0.070 |
Why?
|
| Anxiety Disorders | 2 | 2022 | 322 | 0.070 |
Why?
|
| Data Interpretation, Statistical | 1 | 2009 | 125 | 0.070 |
Why?
|
| Antioxidants | 2 | 2012 | 443 | 0.070 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2008 | 51 | 0.070 |
Why?
|
| Diet Records | 1 | 2008 | 58 | 0.070 |
Why?
|
| Mortality | 1 | 2009 | 175 | 0.070 |
Why?
|
| Automobile Driving | 2 | 2007 | 25 | 0.070 |
Why?
|
| Models, Statistical | 1 | 2009 | 195 | 0.070 |
Why?
|
| Diagnostic Techniques, Ophthalmological | 2 | 2011 | 14 | 0.070 |
Why?
|
| Choroidal Neovascularization | 1 | 2007 | 5 | 0.070 |
Why?
|
| Chronic Disease | 1 | 2011 | 549 | 0.070 |
Why?
|
| Distance Perception | 1 | 2007 | 2 | 0.070 |
Why?
|
| Estrogen Receptor alpha | 1 | 2008 | 121 | 0.070 |
Why?
|
| Fluorescein Angiography | 1 | 2007 | 8 | 0.060 |
Why?
|
| Drug Prescriptions | 1 | 2007 | 60 | 0.060 |
Why?
|
| Students | 1 | 2013 | 626 | 0.060 |
Why?
|
| Geriatric Assessment | 1 | 2007 | 66 | 0.060 |
Why?
|
| Estrogens | 1 | 2008 | 203 | 0.060 |
Why?
|
| Regression Analysis | 3 | 2017 | 490 | 0.060 |
Why?
|
| Health Services | 1 | 2007 | 61 | 0.060 |
Why?
|
| ROC Curve | 2 | 2024 | 159 | 0.060 |
Why?
|
| Functional Laterality | 1 | 2007 | 89 | 0.060 |
Why?
|
| Bone Density | 1 | 2007 | 103 | 0.060 |
Why?
|
| Feasibility Studies | 1 | 2007 | 259 | 0.060 |
Why?
|
| Calcium Channels, N-Type | 2 | 2017 | 8 | 0.060 |
Why?
|
| Prescriptions | 1 | 2006 | 19 | 0.060 |
Why?
|
| Animals | 4 | 2020 | 16992 | 0.060 |
Why?
|
| Transcription Factors | 1 | 2011 | 735 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 3 | 2014 | 455 | 0.060 |
Why?
|
| Sex Factors | 2 | 2025 | 1028 | 0.060 |
Why?
|
| Polypropylenes | 1 | 2005 | 4 | 0.060 |
Why?
|
| Silicone Elastomers | 1 | 2005 | 3 | 0.060 |
Why?
|
| Depression | 2 | 2004 | 863 | 0.060 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2025 | 11 | 0.060 |
Why?
|
| Intraoperative Complications | 3 | 2010 | 20 | 0.060 |
Why?
|
| Nigeria | 1 | 2025 | 92 | 0.060 |
Why?
|
| Cerebrospinal Fluid Pressure | 1 | 2025 | 3 | 0.060 |
Why?
|
| Wounds and Injuries | 1 | 2006 | 193 | 0.060 |
Why?
|
| Managed Care Programs | 1 | 2005 | 40 | 0.060 |
Why?
|
| Epithelium, Corneal | 1 | 2004 | 10 | 0.060 |
Why?
|
| Cysts | 1 | 2004 | 10 | 0.060 |
Why?
|
| Genotype | 3 | 2014 | 800 | 0.050 |
Why?
|
| Ultraviolet Rays | 1 | 2025 | 118 | 0.050 |
Why?
|
| Cholesterol, LDL | 1 | 2024 | 73 | 0.050 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2025 | 94 | 0.050 |
Why?
|
| Hyperlipidemias | 1 | 2024 | 48 | 0.050 |
Why?
|
| Nonoxynol | 1 | 2024 | 1 | 0.050 |
Why?
|
| Cloprostenol | 1 | 2003 | 3 | 0.050 |
Why?
|
| Health Status Indicators | 1 | 2004 | 90 | 0.050 |
Why?
|
| Drug Combinations | 1 | 2003 | 104 | 0.050 |
Why?
|
| Safety | 1 | 2003 | 54 | 0.050 |
Why?
|
| Amides | 1 | 2003 | 71 | 0.050 |
Why?
|
| Diagnosis, Differential | 2 | 2015 | 238 | 0.050 |
Why?
|
| Cotinine | 1 | 2023 | 44 | 0.050 |
Why?
|
| Eye Foreign Bodies | 1 | 2002 | 1 | 0.050 |
Why?
|
| Silicone Oils | 1 | 2002 | 1 | 0.050 |
Why?
|
| False Negative Reactions | 2 | 2018 | 10 | 0.050 |
Why?
|
| Equipment Design | 2 | 2015 | 145 | 0.050 |
Why?
|
| Certification | 1 | 2002 | 21 | 0.050 |
Why?
|
| Probability | 2 | 2013 | 82 | 0.050 |
Why?
|
| Trabecular Meshwork | 1 | 2021 | 10 | 0.050 |
Why?
|
| Protein Stability | 1 | 2021 | 48 | 0.040 |
Why?
|
| Age of Onset | 1 | 2021 | 114 | 0.040 |
Why?
|
| Denmark | 1 | 2021 | 1 | 0.040 |
Why?
|
| Epithelial Cells | 1 | 2004 | 434 | 0.040 |
Why?
|
| Hemorrhage | 1 | 2021 | 55 | 0.040 |
Why?
|
| Occupations | 1 | 2021 | 27 | 0.040 |
Why?
|
| Fathers | 1 | 2021 | 38 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2020 | 33 | 0.040 |
Why?
|
| Aspirin | 1 | 2021 | 89 | 0.040 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2021 | 146 | 0.040 |
Why?
|
| Stents | 1 | 2020 | 67 | 0.040 |
Why?
|
| Capillaries | 1 | 2019 | 27 | 0.040 |
Why?
|
| Organ Size | 1 | 2020 | 170 | 0.040 |
Why?
|
| Blood Flow Velocity | 1 | 2019 | 87 | 0.040 |
Why?
|
| Venules | 1 | 2019 | 1 | 0.040 |
Why?
|
| Arterioles | 1 | 2019 | 19 | 0.040 |
Why?
|
| Medical Records | 2 | 2011 | 48 | 0.040 |
Why?
|
| Fovea Centralis | 1 | 2017 | 3 | 0.030 |
Why?
|
| Spheroids, Cellular | 1 | 2017 | 37 | 0.030 |
Why?
|
| Amino Acid Substitution | 1 | 2017 | 135 | 0.030 |
Why?
|
| Molecular Chaperones | 1 | 2017 | 70 | 0.030 |
Why?
|
| Conjunctiva | 1 | 2016 | 6 | 0.030 |
Why?
|
| Dermis | 1 | 2016 | 9 | 0.030 |
Why?
|
| Haplotypes | 1 | 2017 | 197 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2016 | 60 | 0.030 |
Why?
|
| Extracellular Matrix | 1 | 2017 | 131 | 0.030 |
Why?
|
| Cell Adhesion | 1 | 2017 | 238 | 0.030 |
Why?
|
| Prosthesis Failure | 1 | 2015 | 19 | 0.030 |
Why?
|
| Mobility Limitation | 1 | 2015 | 21 | 0.030 |
Why?
|
| Device Approval | 1 | 2015 | 1 | 0.030 |
Why?
|
| Iran | 1 | 2015 | 202 | 0.030 |
Why?
|
| Diffusion of Innovation | 1 | 2015 | 38 | 0.030 |
Why?
|
| Cytomegalovirus Retinitis | 1 | 2014 | 1 | 0.030 |
Why?
|
| Insurance, Health | 1 | 2016 | 145 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 2016 | 506 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2015 | 115 | 0.030 |
Why?
|
| Sensory Thresholds | 2 | 2005 | 13 | 0.030 |
Why?
|
| Chromosome Mapping | 1 | 2015 | 199 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2015 | 118 | 0.030 |
Why?
|
| Lens Diseases | 1 | 2014 | 1 | 0.030 |
Why?
|
| Iris Diseases | 1 | 2014 | 2 | 0.030 |
Why?
|
| Japan | 1 | 2015 | 348 | 0.030 |
Why?
|
| Biometry | 1 | 2014 | 34 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2015 | 508 | 0.030 |
Why?
|
| Hela Cells | 1 | 2015 | 376 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2017 | 704 | 0.020 |
Why?
|
| Cost Savings | 1 | 2013 | 18 | 0.020 |
Why?
|
| Clinical Competence | 1 | 2014 | 156 | 0.020 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2012 | 30 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2017 | 1271 | 0.020 |
Why?
|
| Diet Surveys | 1 | 2012 | 99 | 0.020 |
Why?
|
| Eye Diseases, Hereditary | 1 | 2011 | 2 | 0.020 |
Why?
|
| Abnormalities, Multiple | 1 | 2011 | 38 | 0.020 |
Why?
|
| Pedigree | 1 | 2011 | 94 | 0.020 |
Why?
|
| Hotlines | 1 | 2011 | 16 | 0.020 |
Why?
|
| Heterozygote | 1 | 2011 | 110 | 0.020 |
Why?
|
| Medically Uninsured | 1 | 2011 | 65 | 0.020 |
Why?
|
| Corneal Edema | 1 | 2010 | 1 | 0.020 |
Why?
|
| Ophthalmodynamometry | 1 | 2010 | 1 | 0.020 |
Why?
|
| Likelihood Functions | 1 | 2010 | 62 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2011 | 142 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2015 | 1869 | 0.020 |
Why?
|
| Internet | 1 | 2011 | 236 | 0.020 |
Why?
|
| Base Sequence | 1 | 2011 | 983 | 0.020 |
Why?
|
| Homeostasis | 1 | 2010 | 192 | 0.020 |
Why?
|
| Diplopia | 1 | 2008 | 1 | 0.020 |
Why?
|
| Phenotype | 1 | 2011 | 780 | 0.020 |
Why?
|
| Pigment Epithelium of Eye | 1 | 2008 | 33 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2011 | 1542 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2008 | 206 | 0.020 |
Why?
|
| Fibrosis | 1 | 2008 | 169 | 0.020 |
Why?
|
| Absorptiometry, Photon | 1 | 2007 | 76 | 0.020 |
Why?
|
| Death Certificates | 1 | 2006 | 15 | 0.020 |
Why?
|
| Systole | 1 | 2006 | 67 | 0.020 |
Why?
|
| Diastole | 1 | 2006 | 47 | 0.020 |
Why?
|
| Drug Costs | 1 | 2006 | 35 | 0.010 |
Why?
|
| Equipment Safety | 1 | 2005 | 5 | 0.010 |
Why?
|
| Recurrence | 1 | 2005 | 152 | 0.010 |
Why?
|
| Cryotherapy | 1 | 2004 | 11 | 0.010 |
Why?
|
| Random Allocation | 1 | 2004 | 147 | 0.010 |
Why?
|
| Mice | 1 | 2015 | 6644 | 0.010 |
Why?
|
| Cognition | 1 | 2007 | 473 | 0.010 |
Why?
|
| Aphakia | 1 | 2002 | 1 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2007 | 925 | 0.010 |
Why?
|
| Drainage | 1 | 2002 | 12 | 0.010 |
Why?
|
| Models, Theoretical | 1 | 2004 | 232 | 0.010 |
Why?
|
| Medical Audit | 1 | 2002 | 26 | 0.010 |
Why?
|
| Self Disclosure | 1 | 2002 | 44 | 0.010 |
Why?
|
| Decision Making | 1 | 2004 | 249 | 0.010 |
Why?
|